TABLE 1

Overview of marketed IgGs and IgG Fc-fusion proteins administered via the subcutaneous route

Data on time to maximum serum concentration and bioavailability collected from the European Medicines Agency (EMA) Summary of Product Characteristics (http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid=), EMA assessment reports, or the Food and Drug Administration homepage (http://www.accessdata.fda.gov/scripts/cder/drugsatfda).

INN Name	Trade Name	Antibody Type	Target	T_max in Humans	Bioavailability in Humans and Animals
				days	%
Adalimumab	Humira	IgG1	TNF	5.5	Humans: 64
Adalimumab	Humira	IgG1	TNF	5.5	Cynomolgus monkey: 96
Canakinumab	Ilaris	IgG1	IL-1β	7	Humans: 70
Canakinumab	Ilaris	IgG1	IL-1β	7	Marmoset: 60
Denosumab	Prolia	IgG2	RANK-L	10	Humans: 78
					Mice: 86
					Cynomolgus monkey: 28–100^{^a}
Golimumab	Simponi	IgG1	TNF	2–6	Humans: 53
Golimumab	Simponi	IgG1	TNF	2–6	Cynomolgus monkey: 77
Omalizumab	Xolair	IgG1	IgE	7–8	Humans: 62
					Mice: 90
					Cynomolgus monkey: 64–104
Rituximab	Mabthera	IgG1	CD20	3	Humans: 71
					Mice: 63
					Minipig: 71
Tocilizumab	Actemra / RoActemra	IgG1	IL-6R	—	Humans: 80
					Minipig: 84
					Cynomolgus monkey: 72
Trastuzumab	Herceptin	IgG1	HER2	3	Humans: 82
					Mice: 83
					Minipigs: 82
					Cynomolgus monkey: ca. 100
Ustekinumab	Stelara	IgG1	IL-12/23p40	8.5	Humans: 57 (24–95)
Ustekinumab	Stelara	IgG1	IL-12/23p40	8.5	Cynomolgus monkey: 97
Abatacept	Orencia	Fc-fusion protein	CD80/86	3–5	Humans: 79
					Mice: 78–110
					Rat: 41-63
Etanercept	Enbrel	Fc-fusion protein	TNF	3	Humans: 76
					Mice: 58
					Cynomolgus monkey: 73
Rilonacept	Arcalyst	Fc-fusion protein	IL-1α, IL-1β, IL-1ra	—	Humans: 43
					Mice: 78
					Rats: 54
					Cynomolgus monkey: 70
Romiplostim	Nplate	Fc-fusion protein	Thrombopoietin receptor	0.6	Humans: –
					Rats: 21–28
					Cynomolgus monkey: 19
					Rhesus monkey: 45–74

CD, Cluster of Differentiation; HER2, human epidermal growth factor receptor 2; IL, interleukin; INN, international nonproprietary name; RANK-L, receptor activator of nuclear factor-κB ligand; TNF, tumor necrosis factor.
↵^a Bioavailability increases with increasing dose.